Actively Recruiting
Phase I Study of TPD3310 Injection to Evaluate Safety, Dosage, and Early Effectiveness in Adults with Advanced Malignant Solid Tumors
Led by TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD. · Updated on 2026-07-20
112
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating TPD3310, a new drug designed to selectively degrade c-MET, in patients with advanced malignant solid tumors. This first-in-human, open-label phase I study is divided into two parts Phase Ia focuses on dose escalation to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and initial signs of effectiveness. Phase Ib expands the study to specific tumor types based on Phase Ia results to further evaluate the drugs effects. In Phase Ia, participants receive TPD3310 injections once weekly at escalating doses ranging from 50 mg to 650 mg over 21 days in a 28-day cycle. Phase Ib involves cohort expansion where dosing follows the recommended regimen from Phase Ia. This study design helps determine the best dose and evaluates TPD3310 in various solid tumors including lung, esophageal, gastric, liver, pancreatic, and renal cancers, focusing on patients who have not responded to or cannot tolerate standard treatments. Participants will undergo regular assessments including safety monitoring, tumor response evaluations based on RECIST criteria, and pharmacokinetic and pharmacodynamic measurements throughout the treatment cycles. The primary outcomes include dose-limiting toxicities, maximum tolerated dose, and objective response rate, with follow-up for up to two years to track disease control, progression-free survival, and overall survival. Safety and toxicity profiles will be closely monitored during and up to 28 days after the last dose to ensure participant well-being.
CONDITIONS
Brief Title
A Study of TPD3310 in Patients With Advanced Malignant Tumors
Research Team
N
Ning Li, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here